Breast Cancer Research and Treatment

, Volume 35, Issue 1, pp 97–104 | Cite as

Ha-ras rare alleles in breast cancer susceptibility

  • Kathleen Conway
  • Sharon Edmiston
  • Daniel B. Fried
  • Barbara S. Hulka
  • Peter A. Garrett
  • Edison T. Liu


Over the last several years, evidence has accumulated to support the idea that rare Ha-ras polymorphisms are associated with inherited susceptibility to certain human cancers. A recent epidemiologic study conducted at our institution found a significant association specifically with breast cancer, although the mechanism underlying this relationship remains unclear. We have proposed that rare Ha-ras alleles are markers of a genomic instability that predisposes to breast cancer. To address this hypothesis, we are investigating the relationship between the presence of rare alleles and another form of instability, gene amplification, and are developing new methodologies both to improve VNTR allele length detection and to characterize the internal repeat sequence variations of the various alleles. These studies should enable us to more clearly define the role of this region in cancer development by delineating VNTR structure and function and the mechanisms of rare allele generation. Ultimately, we hope to identify VNTR characteristics that will permit more accurate cancer risk assessment.

Key words

breast cancer gene amplification genomic instability polymorphisms ras alleles VNTR (variable number tandem repeat) 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harris JR, Lippman ME, Veronesi U, Willett W: Breast cancer. N Engl J Med 327:319–328, 1992.Google Scholar
  2. 2.
    Hall J, Lee M, Newman B, Morrow J, Huey B, King M-C: Linkage of early onset familial breast cancer to chromosome 17q21. Science 250:1684–1689, 1990.Google Scholar
  3. 3.
    Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, Lenoir GM: Familial breast-ovarian cancer locus on chromosome 17q12–q23. Lancet 338: 82–83, 1991.Google Scholar
  4. 4.
    Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstein B, Davidson N: Inherited p53 gene mutations in breast cancer. Cancer Res 52:2984–2986, 1992.Google Scholar
  5. 5.
    Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238, 1990.Google Scholar
  6. 6.
    Zuppan P, Hall JM, Lee MK, Ponglikitmongkol M, King M-C: Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease. Am J Hum Genet 48:1065–1068, 1991.Google Scholar
  7. 7.
    Wooster R, Mangion J, Eeles R, Smith S, Dowsett M, Averill D, Barrett-Lee P, Easton DF, Ponder BAJ, Stratton MR: A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nature Genet 2:132–134, 1992.Google Scholar
  8. 8.
    Lobaccaro J-M, Lumbroso S, Belon C, Galtier-Dereure F, Bringer J, Lesimple T, Heron J-F, Pujol H, Sultan C: Male breast cancer and the androgen receptor gene. Nature Genet 5:109–110, 1993.Google Scholar
  9. 9.
    Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunteun J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon-Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldgar DE, Stratton MR: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science, in press.Google Scholar
  10. 10.
    Krontiris TG, DiMarino NA, Colb M, Parkinson DR: Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature 313:369–374, 1985.Google Scholar
  11. 11.
    Lidereau R, Escot C, Theillet C, Champeme M-H, Brunet M, Gest J, Callahan R: High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J Natl Cancer Inst 77:697–701, 1986.Google Scholar
  12. 12.
    Corell B, Zoll B: Comparison between the allelic frequency distribution of the Ha-rasl locus in normal individuals and patients with lymphoma, breast and ovarian cancer. Hum Genet 79:255–259, 1988.Google Scholar
  13. 13.
    Barkardottir RB, Johannsson OT, Arason A, Gudnason V, Egilsson V: Polymorphism of the c-Ha-ras-1 protooncogene in sporadic and familial breast cancer. Int J Cancer 44:251–255, 1989.Google Scholar
  14. 14.
    Hall JM, Huey B, Morrow J, Newman B, Lee M, Jones E, Carter C, Buehring GC, King M-C: Rare HRAS alleles and susceptibility to human breast cancer. Genomics 6:188–191, 1990.Google Scholar
  15. 15.
    Sheng ZM, Martine G, Gabillet M, Spielman M, Riou G: c-Ha-ras-1 polymorphism in breast cancer patients and a control population. Oncogene Res 2:245–250, 1988.Google Scholar
  16. 16.
    Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N: An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 329:517–523, 1993.Google Scholar
  17. 17.
    Krontiris TG, DiMartino NA, Colb M, Mitcheson HD, Parkinson DR: Human restriction fragment length polymorphisms and cancer risk assessment. J Cell Biochem 30:319–329, 1986.Google Scholar
  18. 18.
    Gerhard DS, Dracopoli NC, Bale SJ, Houghton AN, Payne CE, Greene ME, Housman DE: Evidence against Ha-ras-1 involvement in sporadic and familial melanoma. Nature 325:73–75, 1987.Google Scholar
  19. 19.
    Wyllie FS, Wynford-Thomas V, Lemoine NR, Williams GT, Williams ED, Wynford-Thomas D: Ha-ras restriction fragment length polymorphisms in colorectal cancer. Br J Cancer 57:135–138, 1988.Google Scholar
  20. 20.
    Diedrich U, Eckermann O, Schmidtke J: Rare Ha-ras and c-mos alleles in patients with intracranial tumors. Neurology 38:587–589, 1988.Google Scholar
  21. 21.
    Sugimura H, Caporaso NE, Hoover RN, Resau JH, Trump BF, Lonergaan JA, Krontiris TG, Maann DL, Weston A, Harris CC: Association of rare alleles of the Harvey ras protooncogene locus with lung cancer. Cancer Res 50:1857–1862, 1990.Google Scholar
  22. 22.
    Weston A, Vineis P, Caporaso NE, Krontiris TG, Lonergan JA, Sugimura H: Racial variation in the distribution of Ha-ras-1 alleles. Molec Carcinogenesis 4:265–268, 1991.Google Scholar
  23. 23.
    Garrett PA, Hulka BS, Kim YL, Farber RA: HRAS protooncogene polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 2:131–138, 1993.Google Scholar
  24. 24.
    Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV: Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 302:33–37, 1983.Google Scholar
  25. 25.
    Trepicchio WL, Krontiris TG: Members of therell NK-кB family of transcriptional regulatory proteins bind theHRAS1 minisatellite DNA sequence. Nucl Acids Res 20:2427–2434, 1992.Google Scholar
  26. 26.
    Cohen JB, Walter MV, Levinson AD: A repetitive sequence element 3' of the human c-Ha-ras1 gene has enhancer activity. J Cell Physiol (Suppl) 5:75–81, 1987.Google Scholar
  27. 27.
    Spandidos DA, Holmes L: Transcriptional enhancer activity in the variable tandem repeat DNA sequence downstream of the human Ha-ras1 gene. FEBS Lett 218:41–46, 1987.Google Scholar
  28. 28.
    Green M, Krontiris TG: Allelic variation of reporter gene activation by the HRAS1 minisatellite. Genomics 17:429–434, 1993.Google Scholar
  29. 29.
    Rochlitz CF, Scott GK, Dodson JM, Liu E: Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 49:357–360, 1989.Google Scholar
  30. 30.
    Barbacid M: ras genes. Ann Rev Biochem 56:779–827, 1987.Google Scholar
  31. 31.
    Ohuchi N, Thor A, Page DL, Hand PH, Halter SA, Schlom J: Expression of the 21,000 molecular weight protein in a spectrum of benign and malignant human mammary tissues. Cancer Res 46:2511–2519, 1986.Google Scholar
  32. 32.
    Liu E, Thor A, He M, Barcos M, Ljung B-M, Benz C: The HER2 (c-erbB-2) oncogene is frequently amplified inin situ carcinomas of the breast. Oncogene 7:1027–1032, 1992.Google Scholar
  33. 33.
    Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50:6701–6707, 1990.Google Scholar
  34. 34.
    Schuuring E, Verhoeven E, Mooi WJ, Michalides RJAM: Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 7:355–361, 1992.Google Scholar
  35. 35.
    Escot C, Theillet C, Lidereau R, Spyratos F, Champeme M-H, Gest J, Callahan R: Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 83:4834–4838, 1986.Google Scholar
  36. 36.
    Bonilla M, Ramirez M, Lopez-Cueto J, Gariglio P:In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst 80:665–671, 1988.Google Scholar
  37. 37.
    Tanner MM, Tirkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R, Kowbel D, Shadravan F, Hintz M, Kuo W-L, Waldman FM, Isola JJ, Gray JW, Kallioniemi O-P: Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res 54:4257–4260, 1994.Google Scholar
  38. 38.
    Neubauer A, Neubauer B, He M, Effert P, Iglehart D, Frye RA, Liu E: Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 7:1019–1025, 1992.Google Scholar
  39. 39.
    Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440, 1994.Google Scholar
  40. 40.
    Jeffreys AJ, MacLeod A, Tamaki K, Neil DL, Monckton DG: Minisatellite repeat coding as a digital approach to DNA typing. Nature 354:204–209, 1991.Google Scholar
  41. 41.
    Ali IU, Lidereau R, Theillet C, Callahan R: Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science 238:185–188, 1987.Google Scholar
  42. 42.
    Winqvist R, Mannermaa A, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee W: Refinement of regional loss of heterozygosity for chromosome 11p15.5 in human breast tumors. Cancer Res 53:4486–4488, 1993.Google Scholar
  43. 43.
    Vachtenheim J, Horakova I, Novotona H: Hypomethylation of CCGG sites in the 3' region of the H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. Cancer Res 54:1145–1148, 1994.Google Scholar
  44. 44.
    Kasperczyk A, DiMarino BA, Krontiris TG: Minisatellite allele diversification: the origin of rare HRAS1 alleles. Am J Hum Genet 47:854–859, 1990.Google Scholar
  45. 45.
    Neil DL, Jeffreys AJ: Digital DNA typing at a second hypervariable locus by minisatellite variant repeat mapping. Hum Molecular Genet 2:1129–1135, 1993.Google Scholar
  46. 46.
    Armour JAL, Harris PC, Jeffreys AJ: Allelic variation at minisatellite MS205 (D16S309): evidence for polarized variability. Hum Molec Genet 2:1137–1145, 1993.Google Scholar
  47. 47.
    Jeffreys AJ, Tamaki K, MacLeod A, Monckton DG, Neil DL, Armour JAL: Complex gene conversion events in germline mutation at human minisatellites. Nature Genet 6:136–145, 1994.Google Scholar
  48. 48.
    Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber JG, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027–1038, 1993.Google Scholar
  49. 49.
    Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M, Guan X-Y, Zhang J, Meltzer PS, Yu J-W, Kao F-T, Chen DJ, Cerosaletti KM, Fournier REK, Todd S, Lewis T, Leach RJ, Naylor SL, Weissenbach J, Mecklin J-P, Jarvinen H, Petersen GM, Hamilton SR, Green J, Jass J, Watson P, Lynch HT, Trent JM, de la Chapelle A, Kinzler KW, Vogelstein B: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215–1225, 1993.Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Kathleen Conway
    • 1
    • 2
  • Sharon Edmiston
    • 1
    • 2
  • Daniel B. Fried
    • 1
  • Barbara S. Hulka
    • 1
    • 2
  • Peter A. Garrett
    • 4
  • Edison T. Liu
    • 1
    • 2
    • 3
  1. 1.Department of Epidemiology, School of Public HealthUniversity of North CarolinaNorth CarolinaUSA
  2. 2.Lineberger Comprehensive Cancer CenterUniversity of North CarolinaNorth CarolinaUSA
  3. 3.Department of Medicine, School of MedicineUniversity of North CarolinaNorth CarolinaUSA
  4. 4.The Burroughs Wellcome CompanyResearch Triangle ParkNorth CarolinaUSA

Personalised recommendations